<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35361275</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Print">2055-0294</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>8</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of pharmaceutical health care and sciences</Title>
          <ISOAbbreviation>J Pharm Health Care Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Transfer of brotizolam, periciazine, and sulpiride in cord blood and breast milk, and alprazolam in breast milk: a case report.</ArticleTitle>
        <Pagination>
          <StartPage>10</StartPage>
          <MedlinePgn>10</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">10</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s40780-022-00241-2</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A high prevalence of mental disorders including depression, anxiety, somatoform, and dissociative disorder is reported during pregnancy, however, information on the transfer of antipsychotics across the placenta and into breast milk is limited. We evaluated brotizolam, periciazine and sulpiride in cord blood, maternal serum, and breast milk, and alprazolam in breast milk.</AbstractText>
          <AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">A 38-year-old woman with dissociative disorder was treated with brotizolam, propericiazine, and sulpiride during pregnancy and lactation, and alprazolam during lactation. The drug concentration ratios for both cord blood and maternal serum were 33.3 and 61.5% for brotizolam and sulpiride, respectively, and periciazine (metabolite of propericiazine) was not detected in the cord blood. In breast milk, alprazolam (0.9 ng/mL), sulpiride (445.8 ng/mL), and periciazine (0.3 ng/mL) concentrations were noted at 7.5 h after the last dose on postpartum, whereas brotizolam was not detected. The relative infant doses via breast milk were 1.4, 2.7 and 0.02% of the maternal daily dose, respectively. The neonate had no congenital anomalies and did not experience any severe withdrawal symptoms after birth.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Use of brotizolam, propericiazine, and sulpiride during pregnancy and lactation, and use of alprazolam during lactation were acceptable in this case.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Saito</LastName>
            <ForeName>Jumpei</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0003-4799-5562</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, National Center for Child Health and Development, Tokyo, Japan. saito-jn@ncchd.go.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tachibana</LastName>
            <ForeName>Yoshiyuki</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Infant and Toddler Mental Health, Department of Psychosocial Medicine, National Center for Child Health and Development, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wada</LastName>
            <ForeName>Yuka Sano</ForeName>
            <Initials>YS</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Neonatology, Center for Maternal-Fetal, Neonatal, and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yakuwa</LastName>
            <ForeName>Naho</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Japan Drug Information Institute in Pregnancy, National Center for Child Health and Development, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kawasaki</LastName>
            <ForeName>Hiroyo</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, National Center for Child Health and Development, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Suzuki</LastName>
            <ForeName>Tomo</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Maternal Medicine, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Obstetrics, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sago</LastName>
            <ForeName>Haruhiko</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Obstetrics, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yamatani</LastName>
            <ForeName>Akimasa</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, National Center for Child Health and Development, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Japan Drug Information Institute in Pregnancy, National Center for Child Health and Development, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Murashima</LastName>
            <ForeName>Atsuko</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Japan Drug Information Institute in Pregnancy, National Center for Child Health and Development, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Maternal Medicine, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Pharm Health Care Sci</MedlineTA>
        <NlmUniqueID>101672177</NlmUniqueID>
        <ISSNLinking>2055-0294</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Lactation</Keyword>
        <Keyword MajorTopicYN="N">Pregnancy</Keyword>
        <Keyword MajorTopicYN="N">Psychiatry</Keyword>
        <Keyword MajorTopicYN="N">Psychotherapy</Keyword>
      </KeywordList>
      <CoiStatement>A Murashima received research grant and lecture fee from Chugai Pharmaceutical, Co., Ltd. All other authors declare no conflicts of interest. Each author has confirmed compliance with the journal’s requirements for authorship.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>5</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35361275</ArticleId>
        <ArticleId IdType="pmc">PMC8973510</ArticleId>
        <ArticleId IdType="doi">10.1186/s40780-022-00241-2</ArticleId>
        <ArticleId IdType="pii">10.1186/s40780-022-00241-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Wallwiener S, Goetz M, Lanfer A, Gillessen A, Suling M, Feisst M, et al.  Epidemiology of mental disorders during pregnancy and link to birth outcome: a large-scale retrospective observational database study including 38,000 pregnancies. Arch Gynecol Obstet. 2019;299:755–763. doi: 10.1007/s00404-019-05075-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00404-019-05075-2</ArticleId>
            <ArticleId IdType="pubmed">30734864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lacroix I, Hurault C, Sarramon MF, Guitard C, Berrebi A, Grau M, et al.  Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol. 2009;65:839–846. doi: 10.1007/s00228-009-0647-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00228-009-0647-2</ArticleId>
            <ArticleId IdType="pubmed">19365629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanley GE, Mintzes B. Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance. BMC Pregnancy Childbirth. 2014;14:242. doi: 10.1186/1471-2393-14-242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2393-14-242</ArticleId>
            <ArticleId IdType="pmc">PMC4223368</ArticleId>
            <ArticleId IdType="pubmed">25048574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aliaga A, Cunillera O, Amador MDC, Aliaga M, Arquerons M, Almeda J. Association between affective disorders presenting before and during pregnancy and pre-term birth, considering socio-demographic factors, obstetric factors, health conditions, and use of medication. Aten Primaria. 2019;51:626–636. doi: 10.1016/j.aprim.2018.06.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.aprim.2018.06.009</ArticleId>
            <ArticleId IdType="pmc">PMC6930948</ArticleId>
            <ArticleId IdType="pubmed">30454957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calderon-Margalit R, Qiu C, Ornoy A, Siscovick DS, Williams MA. Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy. Am J Obstet Gynecol. 2009;201:579.e1–579.e5798. doi: 10.1016/j.ajog.2009.06.061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajog.2009.06.061</ArticleId>
            <ArticleId IdType="pmc">PMC2881461</ArticleId>
            <ArticleId IdType="pubmed">19691950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Einarson A, McKenna K, Levinson A. Review: women with schizophrenia have poorer pregnancy outcomes than other women, but it is unclear whether antipsychotic medications affect their infants. Evid Based Ment Health. 2003;6:89. doi: 10.1136/ebmh.6.3.89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ebmh.6.3.89</ArticleId>
            <ArticleId IdType="pubmed">12893800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Convertino I, Sansone AC, Marino A, Galiulo MT, Mantarro S, Antonioli L, et al.  Neonatal adaptation issues after maternal exposure to prescription drugs: withdrawal syndromes and residual pharmacological effects. Drug Saf. 2016;39:903–924. doi: 10.1007/s40264-016-0435-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40264-016-0435-8</ArticleId>
            <ArticleId IdType="pubmed">27289228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Isobe K, Ishii M, Kusaka T. Research on systemic care system for a high risk child management of newborn babies with the withdrawal syndrome. Questionnaire survey on evaluation method by a check list and score table. 1995. https://www.niph.go.jp/wadai/mhlw/1994/h061142.pdf. Accessed 20 Mar 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Aono T, Shioji T, Aki T, Hirota K, Nomura A, Kurachi K. Augmentation of puerperal lactation by oral administration of sulpiride. J Clin Endocrinol Metab. 1979;48:478–482. doi: 10.1210/jcem-48-3-478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jcem-48-3-478</ArticleId>
            <ArticleId IdType="pubmed">429499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saito J, Ishii M, Miura Y, Yakuwa N, Kawasaki H, Suzuki T, et al.  Brotizolam during pregnancy and lactation: Brotizolam levels in maternal serum, cord blood, breast milk, and neonatal serum. Breastfeed Med. 2021;16:579–582. doi: 10.1089/bfm.2021.0013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/bfm.2021.0013</ArticleId>
            <ArticleId IdType="pubmed">33666494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv. 2002;53:39–49. doi: 10.1176/appi.ps.53.1.39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/appi.ps.53.1.39</ArticleId>
            <ArticleId IdType="pubmed">11773648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bai M, Ma Z, Sun D, Zheng C, Weng Y, Yang X, et al.  Multiple drug transporters mediate the placental transport of sulpiride. Arch Toxicol. 2017;91:3873–3884. doi: 10.1007/s00204-017-2008-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00204-017-2008-8</ArticleId>
            <ArticleId IdType="pubmed">28597291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oo CY, Kuhn RJ, Desai N, Wright CE, McNamara PJ. Pharmacokinetics in lactating women: prediction of alprazolam transfer into milk. Br J Clin Pharmacol. 1995;40:231–236. doi: 10.1111/j.1365-2125.1995.tb05778.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2125.1995.tb05778.x</ArticleId>
            <ArticleId IdType="pmc">PMC1365102</ArticleId>
            <ArticleId IdType="pubmed">8527284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furugen A, Nishimura A, Kobayashi M, Umazume T, Narumi K, Iseki K. Quantification of eight benzodiazepines in human breastmilk and plasma by liquid-liquid extraction and liquid-chromatography tandem mass spectrometry: application to evaluation of alprazolam transfer into breastmilk. J Pharm Biomed Anal. 2019;168:83–93. doi: 10.1016/j.jpba.2019.02.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpba.2019.02.011</ArticleId>
            <ArticleId IdType="pubmed">30798209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishimura A, Furugen A, Umazume T, Kitamura S, Soma M, Noshiro K, et al.  Benzodiazepine concentrations in the breast milk and plasma of nursing mothers: estimation of relative infant dose. Breastfeed Med. 2021;16:424–431. doi: 10.1089/bfm.2020.0259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/bfm.2020.0259</ArticleId>
            <ArticleId IdType="pubmed">33449825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ylikorkala O, Kauppila A, Kivinen S, Viinikka L. Sulpiride improves inadequate lactation. Br Med J (Clin Res Ed) 1982;285:249–251. doi: 10.1136/bmj.285.6337.249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.285.6337.249</ArticleId>
            <ArticleId IdType="pmc">PMC1499674</ArticleId>
            <ArticleId IdType="pubmed">6807435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ylikorkala O, Kauppila A, Kivinen S, Viinikka L. Treatment of inadequate lactation with oral sulpiride and buccal oxytocin. Obstet Gynecol. 1984;63:57–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6361642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>SJ OH, Wong A, Joyce DA. A liquid chromatography-tandem mass spectrometry method for quantifying amisulpride in human plasma and breast milk, applied to measuring drug transfer to a fully breast-fed neonate. Ther Drug Monit. 2016;38:493–498. doi: 10.1097/FTD.0000000000000300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/FTD.0000000000000300</ArticleId>
            <ArticleId IdType="pubmed">27027463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanemura A, Masamoto H, Kinjo T, Mekaru K, Yoshida T, Goya H, et al.  Evaluation of neonatal withdrawal syndrome in neonates delivered by women taking psychotropic or anticonvulsant drugs: A retrospective chart review of the effects of multiple medications and breastfeeding. Eur J Obstet Gynecol Reprod Biol. 2020;254:226–230. doi: 10.1016/j.ejogrb.2020.09.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejogrb.2020.09.008</ArticleId>
            <ArticleId IdType="pubmed">33011505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shyken JM, Babbar S, Babbar S, Forinash A. Benzodiazepines in Pregnancy. Clin Obstet Gynecol. 2019;62:156–167. doi: 10.1097/GRF.0000000000000417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/GRF.0000000000000417</ArticleId>
            <ArticleId IdType="pubmed">30628916</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
